Stock 874 GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDING CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.

Equities

874

CNE100000387

Delayed Hong Kong S.E.
Other stock markets
 09:08:20 14/05/2024 BST 		5-day change 1st Jan Change
23.05 HKD +0.22% Intraday chart for Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. +6.47% +5.98%
04-26 Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-18 Baiyunshan Pharmaceutical's 2023 Profit Rises 2% MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company is in a robust financial situation considering its net cash and margin position.
  • Its low valuation, with P/E ratio at 9.25 and 8.9 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
  • The company shows low valuation levels, with an enterprise value at 0.23 times its sales.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDING CO., LTD. Stock Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.
+5.98% 7.03B
B-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+31.06% 682B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+30.35% 586B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-3.42% 364B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.02% 327B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.27% 285B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.53% 240B
B+
NOVARTIS AG Stock Novartis AG
+10.16% 209B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-8.14% 203B
A+
AMGEN INC. Stock Amgen Inc.
+8.12% 165B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 874 Stock
  4. Ratings Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd.